Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Real-world study of Zercepac (trastuzumab) in HER2-positive breast cancer
ChiCTR2100046223Phase 4Recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- May 2021
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of trastuzumab in breast cancer, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Progression-free survival, Disease-free survival and 1 more. Started May 2021; status: recruiting.
02
Drugs
03
Conditions
breast cancer
Beyond the preview
Go deeper on ChiCTR2100046223.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100046223.